TheEdgeResearch
Home / Stocks / CNTG

Centogene N.V. (CNTG)

NASDAQ Healthcare Medical - Diagnostics & Research
$0.33 ▲ +100.00%
Market Cap
$9.4M
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Beta
-0.67
52-Wk Range
0.325-0.429
CEO
Kim Stratton
Country
DE
Currency
USD

Centogene N.V. operates in the Medical - Diagnostics & Research industry of the Healthcare sector, headquartered in Rostock, DE. The stock last traded at $0.33, up 100.00% on the session, giving a market capitalisation of $9.4M. On trailing twelve-month figures it carries a trailing P/E of -0.22, a net margin of -73.2%. Its beta of -0.67 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-0.22
Price / Sales
0.17
Price / Book
-0.31
EV / EBITDA
-3.62
Gross margin
35.5%
Operating margin
-61.1%
Net margin
-73.2%
Return on equity
Debt / equity
-3.18
Current ratio
1.02
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Global Market
Employees
384
IPO date
2019-11-07
Headquarters
Rostock, DE
About Centogene N.V.

Centogene N.V., along with its affiliates, operates globally with a primary focus on rare diseases. The company excels at converting diverse real-world data—spanning clinical, genetic, and other sources—into practical insights for patients, medical professionals, and pharmaceutical enterprises worldwide. Its activities are organized across three core divisions: Pharmaceutical, Diagnostics, and COVID-19 testing. At the heart of Centogene's strategy is its unique rare disease platform, a comprehensive repository of biological samples and integrated data. This platform consolidates epidemiological, phenotypic, and heterogenetic information, significantly improving the identification and ongoing surveillance of rare hereditary conditions. Furthermore, it plays a crucial role in accelerating the development of orphan drugs. The company provides an array of services within its Pharmaceutical segment, including target identification, early patient recruitment, epidemiological intelligence, biomarker discovery, and patient monitoring. Its Diagnostics arm offers genetic sequencing and diagnostic testing, reaching physicians, laboratories, and hospitals directly or through established distribution channels. Centogene also supplies COVID-19 testing solutions, covering both PCR and antigen tests. Established in 2006 and based in Rostock, Germany, Centogene N.V. holds key collaborative and licensing agreements with prominent partners such as Shire International GmbH, Pfizer Inc., Dr. Bauer Laboratoriums GmbH, Fraport AG, Takeda Pharmaceutical Company Limited, and Twist Bioscience Corporation.

Comparable companies

Centogene N.V. is most often compared with the following Healthcare names:

APGNCHROCJJDEPIXETAOFIMVIFNLTXNUROOSATNFA
More research on CNTG
CNTG technical analysis CNTG TheEdge Score Compare against peers
Open full interactive analysis & DCF →